Coherent Biopharma

Executive Summary

Coherent Biopharma (CBP) is a clinical-stage biopharmaceutical company pioneering bi-targeting XDC (X-Drug Conjugate) technology to address undruggable targets in oncology. With a proprietary platform enabling precise delivery of bioactive molecules, CBP has built a pipeline of multiple clinical-stage assets and operates globally with integrated management in China, the U.S., and Australia. The company's innovative approach holds promise for overcoming limitations of traditional drug conjugates, potentially offering improved efficacy and safety profiles. As a privately held entity with over 110 employees, CBP is advancing its lead candidates through Phase 2 trials, positioning itself for potential value inflection points from upcoming data readouts and strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead XDC candidate in solid tumors60% success
• Q1 2027Initiation of pivotal Phase 3 trial for lead asset70% success
• H2 2026Potential strategic partnership or licensing deal for pipeline assets50% success